SCHEMBL465479

SCHEMBL465479

CCCOc1ccc2[nH]c(-c3ccc(OCCOc4ccc(-c5nc6cc(OCCC)ccc6[nH]5)cc4)cc3)nc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 9/20 0.54
CHRNB4 P30926 1/20 0.54
CHRNA3 P32297 1/20 0.54
CHRNA7 P36544 1/20 0.54
ATP4A P20648 1/20 0.54
ATP4B P51164 1/20 0.54
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
TP53 P04637 3/20 0.51
MAPT P10636 3/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
NPC1 O15118 2/20 0.51
HSD17B10 Q99714 2/20 0.51
ALOX12 P18054 1/20 0.51
KDM4E B2RXH2 1/20 0.51
USP2 O75604 1/20 0.51
LMNA P02545 1/20 0.51
TSHR P16473 1/20 0.51
NFKB1 P19838 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11624627 0.84 ACHE (0.74) ACHECHRNB4CHRNA3CHRNA7ATP4A
SCHEMBL31063784 0.84 ACHE (0.74) ACHECHRNB4CHRNA3CHRNA7ATP4A
SCHEMBL465477 0.82 NPC1 (0.56) ACHECHRNB4CHRNA3CHRNA7ATP4A
SCHEMBL20982723 0.82 CHEK2 (0.61) ACHEPLGPLAU
SCHEMBL465444 0.82 ACHE (0.64) ACHECHRNB4CHRNA3CHRNA7TP53
SCHEMBL9636322 0.81 ACHE (0.52) ACHECHRNB4CHRNA3CHRNA7ATP4A
SCHEMBL21017655 0.81 ACHE (0.65) ACHECHRNB4CHRNA3CHRNA7ATP4A
SCHEMBL31289539 0.81 ATP4A (0.55) ACHECHRNB4CHRNA3CHRNA7ATP4A
SCHEMBL10733269 0.81 CHRNB4 (0.54) ACHECHRNB4CHRNA3CHRNA7ATP4A
SCHEMBL21017830 0.79 ACHE (0.73) ACHECHRNB4CHRNA3CHRNA7ATP4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194981-B1 BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS UNIV MONS HAINAUT (BE) 2011-11-23 EP disclosed
US-20100160402-A1 Bisbenzimidazoles as antimalarial agents XAVIER UNIVERSITY OF LOUISIANA 2010-06-24 US disclosed
US-20100160402-A1 Bisbenzimidazoles as antimalarial agents XAVIER UNIVERSITY OF LOUISIANA 2010-06-24 US disclosed
US-20100160402-A1 Bisbenzimidazoles as antimalarial agents XAVIER UNIVERSITY OF LOUISIANA 2010-06-24 US disclosed
EP-2194981-A1 BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS Université de Mons-Hainaut (BE) 2010-06-16 EP disclosed
WO-2009043902-A1 BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS UNIVERSITE DE MONS HAINAUT (BE) 2009-04-09 WO disclosed
WO-2009043902-A1 BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS UNIVERSITE DE MONS HAINAUT (BE) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160402-A1 Bisbenzimidazoles as antimalarial agents NQO2, SQOR, CPS1 ACHE 4166/4885CHRNB4 4288/4885CHRNA3 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.